AML
Conditions
Brief summary
In this open-label, prospective clinical trial, the investigators enrolled acute myeloid leukemia (AML) patients after consolidation therapy. Patients with minimal residual disease (MRD) receive decitabine treatment if patients do not receive stem cell transplantation. The MRD clearance rate is the primary outcome to measure the efficacy of decitabine regimen.
Detailed description
In this open-label, prospective clinical trial, acute myeloid leukemia (AML) patients after consolidation therapy are enrolled. Patients with minimal residual disease (MRD) after consolidation therapy receive decitabine treatment if patients do not receive stem cell transplantation. The treatment regimen includes three course of decitabine regimen at a dose of 20mg/m² on day1-5. The MRD clearance rate is the primary outcome to measure the efficacy of decitabine regimen.
Interventions
DRUGDecitabine
Decitabine at a dose of 20mg/㎡/d on day 1-5.
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Age of 14 to 55 years old; 2. Patients that meet the diagnostic criteria(WHO 2008 criteria) of AML after consolidation regimen. 3. Patients who had received induction and consolation therapy and reached CR. 4. ECOG score of ≤ 2; 5. Patients with eligible laboratory examination including liver,renal and heart function. 6. Adult patients are willing to participate in the study and sign the informed consent by themselves or by their immediate family. Patients under 18 years old willing to participate should have their legal guardians sign the informed consent.
Exclusion criteria
1. Secondary leukemia. 2. Patients had other tumor at active stage or had received radiotherapy or chemotherapy in the last 6 months due to other tumor. 3. Patients with other blood diseases(for example, haemophiliacs) are excluded.However, undiagnosed MDS or MPD patients are included. 4. Acute panmyelosis with myelofibrosis and myeloid sarcoma patients; 5. With BCR-ABL fusion gene; 6. Pregnant or lactating women; 7. With ineligible renal or liver function; 8. With active cardiovascular disease; 9. Severe infection disease including uncured tuberculosis pulmonary aspergillosis; 10. AIDS; 11. Patients had central nervous system involvement when they were diagnosed as AML. 12. Patients with epilepsy or dementia or other mental disease who couldn't understand or follow the research. 13. Drugs, medical, mental or social situation may distract patients from following the research or being evaluated the results. 14. Patients with other factors which were considered unsuitable to participate in the study by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MRD Clearance Rate | Within 6 months after decitabine treatment | MRD Clearance Rate is defined as the ratio patients that transform from MRD-positive to MRD-negative after treatment in all of the MRD-positive patients. |
Secondary
| Measure | Time frame |
|---|---|
| Non-relapse Mortality | Within 5 years after treatment |
| Overall Survival Rate (OS) | Within 5 years after treatment |
| Cumulative incidence of relapse | Within 5 years after treatment |
Countries
China
Outcome results
None listed